头孢磺啶也称为“头孢磺苄啶”“头孢磺吡苄”或“磺吡苄头孢菌素”，是一种第三代头孢菌素。该抗生素对绿脓杆菌的活性较强，对肠杆菌也有效。

羧基青霉素：羧苄西林（卡茚西林） · 替卡西林 · 替莫西林 脲基青霉素：阿洛西林 · 哌拉西林 · 美洛西林

医学导航：病菌

细菌（分类）

gr+f／gr+a（t）／gr-p（c／gr-o

药物（J1p、w、n、m、疫苗）

Cefsulodin is a third-generation cephalosporin antibiotic with specific activity against Pseudomonas aeruginosa. It has no significant activity against other Gram-negative bacteria and very limited activity against Gram-positive bacteria and anaerobic bacteria. Cefsulodin was first synthesized and patented by the Takeda Pharmaceutical Company in 1977. In 2002, Takeda stopped production of cefsulodin. Many years of low-stability cefsulodin production has led to a widespread reduction of laboratory and research uses. Current attempts (i.e. IDEXX Laboratories) of increasing purity and stability of cefsulodin center around recrystallization. Typically, the process entails: Cefsulodin is dissolved in an organic solvent, sodium ions, water, or any mixture thereof, then subsequently recrystallized through separation of the unwanted fraction. Recently, TOKU-E has found the main cause of cefsulodin instability stems from one key impurity in 7-aminocephalosporanic acid, a raw material used in the synthesis of cefsulodin. To produce high-purity, high-stability cefsulodin, TOKU-E uses industrial HPLC to remove significant quantities of this impurity in 7-ACA and thus produces ultrapure, ultrastable, and ultrapotent cefsulodin.